摘要
目的探讨吲达帕胺联合氨氯地平治疗高血压合并冠心病的效果和安全性。方法将本院高血压合并冠心病患者70例随机分为观察组和对照组,观察组给予吲达帕胺联合氨氯地平治疗,对照组给予硝苯地平控释片联合氢氯噻嗪片治疗,评估两组临床效果及药物不良反应的发生率。结果观察组总有效率明显高于对照组,两组比较差异有统计学意义(P<0.05)。治疗后观察组收缩压及舒张压均低于对照组,两组比较差异有统计学意义(P<0.05)。观察组不良反应总发生率明显低于对照组,两组比较差异有统计学意义(P<0.05)。结论吲达帕胺联合氨氯地平治疗高血压合并冠心病的效果更好,且安全。
Objective To explore the effect and safety of Indapamide and Amlodipinein treatment of hypertension and coronary heart disease patients. Methods The 70 patients with hypertension and coronary heart disease in our hospital were randomly divided into the observation group and the control group. The observation group received the Indapamide and Amlodipine treatment,the control group received the nifedipine controlled release tablets in combination with hydrogen ticlopidine hydrochloride tablets treatment. The effect and drug adverse reaction rate were evaluated. Results The total effective rate of observation group was significantly higher than that of control group,and there was significant differences between them（ P〈 0. 05）. The systolic blood pressure and diastolic blood pressure of observation group were lower than those of control group,and there was significant differences between them（ P〈0.05）. The incidence of adverse reactions in the observation group was significantly lower than that of the control group,and there was significant differences between them（ P 〈0.05）.Conclusions The efficacy of Indapamide combined with Amlodipinein in treating patients with hypertension and coronary heart disease is better and is safe.
出处
《齐齐哈尔医学院学报》
2016年第26期3290-3291,共2页
Journal of Qiqihar Medical University
关键词
吲达帕胺
氨氯地平
高血压
冠心病
Indapamide
Amlodipine
Hypertension
Coronary heart disease
